NCT05821777 - A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

January 24, 2025

Study Completion Date

September 9, 2025

Conditions

Advanced Solid Tumor

Interventions

DRUG

LB101

Part 1: IV infusion of LB101 Q2W (28-day cycle) and Part 2: IV infusion of LB101

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Sarah Cannon Research Institute at Florida Cancer Specialists, Sarasota

Sarah Cannon Research Institute at Tennessee Oncology Nashville, Nashville

NEXT Oncology - Dallas, Irving

NEXT Oncology, San Antonio

Sarah Cannon Research Institute at HealthONE., Denver

Institut Gustave Roussy, Villejuif